Cargando…
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
Discovery of clinical and genetic predictors of exemestane pharmacokinetics was attempted in 246 post-menopausal patients with breast cancer enrolled on a prospective clinical study. A sample was collected two hours after exemestane dosing at a 1 or 3 month study visit to measure drug concentration....
Autores principales: | Hertz, Daniel L., Kidwell, Kelley M., Seewald, Nicholas J., Gersch, Christina L., Desta, Zeruesenay, Flockhart, David A, Storniolo, Ana-Maria, Stearns, Vered, Skaar, Todd C, Hayes, Daniel F, Henry, N. Lynn, Rae, James M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323433/ https://www.ncbi.nlm.nih.gov/pubmed/27549341 http://dx.doi.org/10.1038/tpj.2016.60 |
Ejemplares similares
-
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016) -
Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes
por: Philips, Santosh, et al.
Publicado: (2012) -
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer
por: Hertz, Daniel L., et al.
Publicado: (2021) -
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013) -
CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)